Abstract 74P
Background
To study tumor’s genetic phenotype in patients with osteosarcoma and estimate long-term results.
Methods
221 patients with osteosarcoma were included to research. The gender ratio was 133 men, 88 women. The age of patients was from 1 to 35 years. The distribution of patients by localization of tumor was as follows: in 102 patients femoral bone damaged by tumor, in 83 patients – in tibialis, in 16 patients – in fibula, in 11 patients in the radial bone, in 6 patients - in iliac bone, and 5 in the humerus. In all cases, the treatment was performed according to the protocol and treatment standard. The tumor markers (P53; Ki67; BcL2) were studied by the method of immunohistochemistry. The combination of P53 + / Ki67 + / Bcl2 - was considered as a negative combination and the combination of P53 - / Ki67- / Bcl2+ as a positive. Depending on the combination of genetic markers, the survival rate of patients was studied by method of Kaplan-Meier.
Results
The 3 and 5-year survival rates of patients with osteosarcoma who had a positive combination of genetic markers (40.0% and 0%) was lower than patients who had negative P53 - / Ri67 - /Bcl2 + (90.0 ± 2.9% and 40.0 ± 4.2%) (P < 0.05). The 3 and 5-year survival rates without metastasis in adverse gene combinations of P53 + / Ki67 + / Bcl2 + was 70.0 ± 3.4% and 10.0 ± 3.2%, while the positive phenotype was - 90.0 ± 3.4% and 50.0 ± 4.3% (P < 0.05). In the analysis, the 3 and 5 year survival rates without recurrent in the negative phenotype was 60.0 ± 4.9% and 10.0 ±4%, whereas in a positive it was 90.03 ± 3.2% and 50.0 ± 4.2% (P < 0.05).
Conclusions
The research shown that, the forecast was adverse in the positive expression of P53+/Ki67+. The tactics in the treatment of osteosarcoma can be changed by combination of these markers.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
N.S. Kamalovich.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
174P - Human adipose stem cells transfer their mitochondria to breast cancer patient derived organoids increasing drug resistance
Presenter: Martina Marigliano
Session: Cocktail & Poster Display session
Resources:
Abstract
175P - Differential impact of increased neoantigen load on PD-L1 positive immune cell infiltrations in comparison to PD-L1 expression on tumor cells
Presenter: Ashok Kumar Vaid
Session: Cocktail & Poster Display session
Resources:
Abstract
176P - Patient race is a determinant of the impact of Y chromosome loss on survival
Presenter: Suhyeon Choi
Session: Cocktail & Poster Display session
Resources:
Abstract
178P - Clinical correlates and impact of ctDNA levels on detecting distinct genomic alteration in patients with metastatic colorectal cancer
Presenter: Luca Boscolo Bielo
Session: Cocktail & Poster Display session
Resources:
Abstract
179P - Identification of guanine-quadruplex forming DNA aptamer: A promising therapeutic strategy for EGFR overexpressed non-small cell lung cancer
Presenter: Deepa Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
180P - Unravelling drug resistance in high-grade serous ovarian cancer through clonal dynamics and single-cell heterogeneity analysis
Presenter: Alvaro Ingles Russo Garces
Session: Cocktail & Poster Display session
Resources:
Abstract
181P - Establishment of primary prostate cancer patient-derived organoids to assess PARP inhibitors antitumor activity beyond synthetic lethality
Presenter: Tatiana P. Grazioso
Session: Cocktail & Poster Display session
Resources:
Abstract
182P - METHRO: Multicentric study of risk of thrombosis in patients with NSCLC harboring a METexon 14 skipping mutation
Presenter: Maria Virginia Sanchez Becerra
Session: Cocktail & Poster Display session
Resources:
Abstract
183P - SomaVar: A web application for somatic variant storage, annotation and classification
Presenter: Sorin Armeanu-Ebinger
Session: Cocktail & Poster Display session
Resources:
Abstract